[1] [2] While high-dose oral B12 supplements can be effective through passive diffusion, they are not routinely recommended for pernicious anaemia management in UK practice
The following comparison illustrates the practical cost difference for a typical patient on a monthly maintenance schedule: For patients with pernicious anemia or severe malabsorption where injections are clinically necessary, this cost is justified and often covered by insurance
The mechanisms driving central sensitization include elevated substance P, reduced descending pain inhibition, altered glutamate signaling, and microglial activation in the central nervous system
Patients received an initial dose of either 1 mg, 2 mg, or 4 mg of retatrutide and subsequent doses of either 1 mg, 4 mg, 8 mg, or 12 mg, or they received a placebo throughout the 48 weeks of the study
This evidence gap is the single largest limitation of peptide-based approaches